v3.26.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2026
Equity [Abstract]  
Stockholders' Equity

Note 7. Stockholders’ Equity

Series B Preferred Stock and Dividend Accretion

The following table summarizes Series B preferred stock and the accretion of dividend activity for the three months ended March 31, 2026 and 2025 (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

2025

 

Series B Preferred Stock:

 

 

 

Balance at beginning of period

 

$

28,296

 

$

27,472

 

Cumulative dividends on Series B preferred stock

 

 

211

 

 

205

 

Balance at end of period

 

$

28,507

 

$

27,677

 

Number of Common Shares Issuable Upon Conversion:

 

 

 

Number of shares at beginning of period

 

 

7,074

 

 

6,868

 

Cumulative dividends on Series B preferred stock

 

 

53

 

 

51

 

Number of shares at end of period

 

 

7,127

 

 

6,919

 

 

Based on the current conversion price, the outstanding shares, including the accretion of dividends, of Series B preferred stock as of March 31, 2026 would be convertible into 7,126,723 shares of the Company’s common stock. However, the conversion rate will be subject to adjustment in certain instances, such as if the Company issues shares of its common stock at a price less than $4.00 per common share, subject to a minimum conversion price of $3.27 per share. As of March 31, 2026, none of the contingent conditions to adjust the conversion rate had been met.

Each share of Series B preferred stock is entitled to a cumulative annual dividend of 5% for the first six years following the issuance of such share and 3% for each year thereafter, with the Company retaining the option to settle each year’s dividend after the 10th year in cash. The dividends accrue and are payable in kind upon such time as the shares convert into the Company’s common stock. In general, the shares are not entitled to vote except in certain limited cases, including in change of control transactions where the expected price per share distributable to the Company’s stockholders is expected to be less than $4.00 per share. The Certificate of Designation with respect to the Series B preferred stock further provides that in the event of, among other things, any change of control, liquidation or dissolution of the Company, the holders of the Series B preferred stock will be entitled to receive, on a pari passu basis with the holders of the common stock, the same amount and form of consideration that the holders of the Company’s common stock receive (on an as-if-converted-to-common-stock basis and without regard to the Beneficial Ownership Limitation (as defined in the Certificate of Designation) applicable to the Series B preferred stock).

Stock Repurchases

On November 7, 2024, the Company announced that its board of directors authorized a stock repurchase program (the “Stock Repurchase Program”), pursuant to which the Company may purchase up to $10,000,000 of its common stock. Under the Stock Repurchase Program, effective November 15, 2024, the Company may repurchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions, or other means. The timing and amount of shares repurchased depends on a number of factors, including stock price, trading volume, general market and business conditions, liquidity and capital needs, and other factors. The Stock Repurchase Program does not obligate the Company to repurchase any specific dollar amount or acquire any specific number of shares of common stock. The Stock Repurchase Program has no expiration date and may be suspended or discontinued at any time without notice.

As of March 31, 2026, the Company repurchased a total of 463,779 shares of common stock under the Stock Repurchase Program for total consideration of approximately $1.9 million. During the three months ended March 31, 2026, there were no repurchases of shares of common stock under the Stock Repurchase Program.

During the three months ended March 31, 2026, the Company repurchased 108,701 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") issued to employees.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance as of March 31, 2026 was as follows:

 

 

 

Number of Shares

 

Vesting of RSUs, vesting of performance stock units ("PSUs") and issuance of RSUs vested but not released

 

 

1,092,015

 

Employee Stock Purchase Plan

 

 

293,888

 

Shares of common stock available for grant under the 2011 Incentive Compensation Plan

 

 

921,004

 

Shares of common stock issuable upon conversion of Series B preferred stock

 

 

7,541,449

 

Total

 

 

9,848,356